Shares of Kala Pharmaceuticals Inc (NASDAQ:KALA) have earned an average recommendation of “Buy” from the six research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $36.80.
KALA has been the topic of a number of analyst reports. Wedbush reiterated an “outperform” rating and issued a $46.00 price target on shares of Kala Pharmaceuticals in a research note on Thursday, October 19th. J P Morgan Chase & Co set a $35.00 price target on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, November 19th. Zacks Investment Research cut shares of Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Oppenheimer began coverage on shares of Kala Pharmaceuticals in a research note on Tuesday, August 15th. They issued an “outperform” rating and a $46.00 price target on the stock. Finally, Wells Fargo & Company began coverage on shares of Kala Pharmaceuticals in a research note on Monday, August 14th. They set an “outperform” rating and a $24.00 target price on the stock.
Kala Pharmaceuticals (NASDAQ KALA) opened at $18.20 on Wednesday. Kala Pharmaceuticals has a one year low of $13.51 and a one year high of $26.75. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Orbimed Advisors LLC bought a new position in Kala Pharmaceuticals during the 3rd quarter valued at about $54,251,000. Caxton Corp bought a new position in Kala Pharmaceuticals during the 3rd quarter valued at about $12,430,000. Victory Capital Management Inc. bought a new position in Kala Pharmaceuticals during the 3rd quarter valued at about $12,414,000. OxFORD Asset Management LLP bought a new position in Kala Pharmaceuticals during the 3rd quarter valued at about $4,374,000. Finally, JPMorgan Chase & Co. bought a new position in Kala Pharmaceuticals during the 3rd quarter valued at about $4,037,000. Institutional investors and hedge funds own 62.96% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Kala Pharmaceuticals Inc (KALA) Given Average Recommendation of “Buy” by Analysts” was published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/06/kala-pharmaceuticals-inc-kala-given-average-recommendation-of-buy-by-analysts.html.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
What are top analysts saying about Kala Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Kala Pharmaceuticals Inc and related companies.